The cash offer values Bio-Techne at approximately $11.3 billion, drawing attention to the life sciences tools sector.
Merck KGaA agreed to buy Bio-Techne for $73 per share in an all-cash deal, valuing the transaction at roughly $11.3 billion. The acquisition highlights growing consolidation in the life sciences tools and services sector.
Bio-Techne, a provider of biotech and diagnostic solutions, had not been the subject of recent major M&A speculation. The offer represents a premium to its prior closing price, reflecting strong demand for specialized life sciences assets.
The deal is expected to position Merck KGaA as a key player in the sector, though market reaction to the announcement remains limited so far.